Showing results (11-20 of 32) with videos related to
Sort By:
Pageof 4
Leukemia & Lymphoma|July 24, 2019
Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeuticsDavid A Knorr, Aaron D Goldberg, Eytan M Stein, et al.Journal of Hematology|May 5, 2020
Spontaneous Remission in a Patient With Acute Myeloid Leukemia Leading to Undetectable Minimal Residual DiseaseDaniel Helbig, Andres E Quesada, Wenbin Xiao, et al.Blood|April 15, 2009
Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activityPetter S Woll, Bartosz Grzywacz, Xinghui Tian, et al.Cytotherapy|September 3, 2013
Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft modelMelissa A Geller, David A Knorr, David A Hermanson, et al.Stem Cells Translational Medicine|March 22, 2013
Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapyDavid A Knorr, Zhenya Ni, David Hermanson, et al.Journal of Virology|October 22, 2010
Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanismsZhenya Ni, David A Knorr, Christine L Clouser, et al.Cardio-Oncology (London, England)|November 24, 2021
Differentiation syndrome-induced Myopericarditis in the induction therapy of acute Promyelocytic leukemia: a case reportShabari Mangalore Shenoy, Thomas Di Vitantonio, Anna Plitt, et al.Biorxiv : the Preprint Server for Biology|February 13, 2023
IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancerJeffrey L Wong, Patrick Smith, Juan Angulo-Lozano, et al.Proceedings of the National Academy of Sciences of the United States of America|August 22, 2023
IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancerJeffrey L Wong, Patrick Smith, Juan Angulo-Lozano, et al.Cell Reports. Medicine|June 3, 2025
Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockadeLucas Blanchard, Estefania Vina, Jerko Ljubetic, et al.Pageof 4